The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases

BACKGROUND: In multidrug regimens, including an intravenous aminoglycoside (e.g. amikacin [AMK]) is recommended for difficult-to-treat non-tuberculous mycobacterial (NTM) lung diseases. We aimed to evaluate the efficacy, safety, and feasibility of inhaled AMK therapy in patients with difficult-to-tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yagi, Kazuma, Ishii, Makoto, Namkoong, Ho, Asami, Takahiro, Iketani, Osamu, Asakura, Takanori, Suzuki, Shoji, Sugiura, Hiroaki, Yamada, Yoshitake, Nishimura, Tomoyasu, Fujiwara, Hiroshi, Funatsu, Yohei, Uwamino, Yoshifumi, Kamo, Tetsuro, Tasaka, Sadatomo, Betsuyaku, Tomoko, Hasegawa, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550988/
https://www.ncbi.nlm.nih.gov/pubmed/28793869
http://dx.doi.org/10.1186/s12879-017-2665-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550988/
https://www.ncbi.nlm.nih.gov/pubmed/28793869
http://dx.doi.org/10.1186/s12879-017-2665-5

Ejemplares similares